At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LXRX Lexicon Pharmaceuticals
Trading 12-09 15:25:51 EST
1.32
-0.07
-4.95%
High1.40Low1.29Vol1.83M
Open1.39D1 Closing1.39Amplitude7.91%
Mkt Cap480.12MTradable Cap242.95MTotal Shares363.40M
T/O2.43MT/O Rate1.00%Tradable Shares183.89M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Lexicon Pharmaceuticals to Present New Sotagliflozin Data on Adipose Distribution in Non-Diabetic HFpEF Patients
Reuters  ·  12-05
Lexicon Pharmaceuticals to Present New Sotagliflozin Data on Adipose Distribution in Non-Diabetic HFpEF Patients
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients Will Be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
THOMSON REUTERS  ·  12-05
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients Will Be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
Lexicon Pharmaceuticals to Present at Piper Sandler and Evercore Healthcare Conferences
Reuters  ·  11-25
Lexicon Pharmaceuticals to Present at Piper Sandler and Evercore Healthcare Conferences
Lexicon Pharmaceuticals Inc Files For Offering Of Up To $75 Million Of Common Stock - SEC Filing
Reuters  ·  11-20
Lexicon Pharmaceuticals Inc Files For Offering Of Up To $75 Million Of Common Stock - SEC Filing
Lexicon Pharmaceuticals Q3 EPS USD -0.04
Reuters  ·  11-20
Lexicon Pharmaceuticals Q3 EPS USD -0.04
Stock Track | Lexicon Pharmaceuticals Surges 5.28% on Upcoming Jefferies Conference Participation
Stock Track  ·  11-12
Stock Track | Lexicon Pharmaceuticals Surges 5.28% on Upcoming Jefferies Conference Participation
Stock Track | Lexicon Pharmaceuticals Soars 5.28% on Upcoming Jefferies Conference Participation
Stock Track  ·  11-12
Stock Track | Lexicon Pharmaceuticals Soars 5.28% on Upcoming Jefferies Conference Participation
Lexicon Pharmaceuticals to Join Jefferies London Healthcare Conference
Reuters  ·  11-11
Lexicon Pharmaceuticals to Join Jefferies London Healthcare Conference
Lexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes
Reuters  ·  11-10
Lexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes
Lexicon announces new sotagliflozin clinical data at AHA Sessions 2025
TIPRANKS  ·  11-10
Lexicon announces new sotagliflozin clinical data at AHA Sessions 2025
Stock Track | Lexicon Pharmaceuticals Plummets 5.24% Pre-Market on $75 Million Stock Offering News
Stock Track  ·  11-07
Stock Track | Lexicon Pharmaceuticals Plummets 5.24% Pre-Market on $75 Million Stock Offering News
Stock Track | Lexicon Pharmaceuticals Plummets 5.24% Following $75 Million Stock Offering Announcement
Stock Track  ·  11-07
Stock Track | Lexicon Pharmaceuticals Plummets 5.24% Following $75 Million Stock Offering Announcement
Stock Track | Lexicon Pharmaceuticals Plunges 7.69% on $75 Million Stock Offering Announcement
Stock Track  ·  11-07
Stock Track | Lexicon Pharmaceuticals Plunges 7.69% on $75 Million Stock Offering Announcement
BRIEF-Lexicon Pharmaceuticals Inc Files For Offering Of Up To $75 Million Of Common Stock - SEC Filing
Reuters  ·  11-07
BRIEF-Lexicon Pharmaceuticals Inc Files For Offering Of Up To $75 Million Of Common Stock - SEC Filing
Lexicon Pharmaceuticals Files Prospectus for Stock Sale
TIPRANKS  ·  11-07
Lexicon Pharmaceuticals Files Prospectus for Stock Sale
Lexicon Pharmaceuticals Inc Files for Offering of up to $75 Mln of Common Stock - SEC Filing
THOMSON REUTERS  ·  11-07
Lexicon Pharmaceuticals Inc Files for Offering of up to $75 Mln of Common Stock - SEC Filing
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Lexicon Pharmaceuticals (LXRX) and Cullinan Management (CGEM)
TIPRANKS  ·  11-07
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR), Lexicon Pharmaceuticals (LXRX) and Cullinan Management (CGEM)
Stock Track | Lexicon Pharmaceuticals Soars 5.05% on Better-Than-Expected Q3 Results and Revenue Surge
Stock Track  ·  11-07
Stock Track | Lexicon Pharmaceuticals Soars 5.05% on Better-Than-Expected Q3 Results and Revenue Surge
Lexicon Pharma Q3 net loss narrows as R&D costs drops
Reuters  ·  11-06
Lexicon Pharma Q3 net loss narrows as R&D costs drops
Lexicon Pharmaceuticals Q3 EPS $(0.04) Beats $(0.07) Estimate, Sales $14.182M Beat $4.649M Estimate
Benzinga  ·  11-06
Lexicon Pharmaceuticals Q3 EPS $(0.04) Beats $(0.07) Estimate, Sales $14.182M Beat $4.649M Estimate

Introduction

Company Name.
Lexicon Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Issue price:
--